Yusuf Z. Şener, MD


Metastatic Renal Cell Carcinoma With Sarcomatoid Features

In this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.

Lindsay Fischer


Axi-Cel Improves Survival Vs SOC in Relapsed/Refractory LBCL

Axicabtagene ciloleucel produces a higher median overall survival vs high-dose therapy plus autologous stem cell transplant among patients with relapsed or refractory large B-cell lymphoma in the phase 3 ZUMA-7 trial.

Daniel H. Ahn, DO


Final Comments on ctDNA Testing in the Management of Colorectal Cancer

The panel shares some closing thoughts on ctDNA testing in patients with colorectal cancer.

Ana Beatriz Fernández Román, PharmG


Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data

Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.

Preet M. Chaudhary, MD, PhD


Treatment Experience for a Patient With GVHD

A patient with GVHD chronicles his treatment experience, and GVHD experts share thoughts on how to approach treatment.

Omar Nadeem, MD


Managing AEs Associated With Bispecifics in RRMM

Closing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.

Michael Lin-Brande, MD


Primary Focal Therapy for Localized Prostate Cancer: A Review of the Literature

Focal therapy for prostate cancer could balance undertreatment and overtreatment of localized prostate cancer for highly selected patients. Long-term oncologic outcomes are not yet available for any modality. Patients should be informed regarding currently available outcomes, the necessity of adherence to a stringent follow-up protocol, and the possible need for additional targeted therapy or future radical treatment in case of recurrence.

Bhumika Patel, MD


Tagraxofusp in BPDCN: Practical Advice and Future Directions in Care

After sharing key takeaways on the management of BPDCN, expert hematologist-oncologists highlight unmet needs and forecast evolutions in care.

Roger Li, MD


Roger Li, MD, Talks Future Analyses of CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBC

Roger Li, MD, spoke about future trials planned for the combination of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.

Inga Lennes, MD, MBA, MPH


Medical World News® After Hours: Thoracic Medical Oncologist Inga Lennes, MD, MBA, MPH, on Healthy Eating

During an After Hours segment of Medical World News®, Inga Lennes, MD, MBA, MPH, spoke about her passion for healthy cooking and how it helps her unwind after a busy week of treating patients.

Barry Hammer, PA-C


Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM

April Logue, APRN-CNP, shares her perspective on selecting between doublet and triplet regimens for patients with transplant-ineligible newly-diagnosed multiple myeloma.

Martha Ann Raymond, MA


Martha Ann Raymond, MA, on What Providers Should Do to Enhance Clinical Trial Participation in the COVID-19 Era

The founding executive director of the GI Cancers Alliance discussed important takeaways from a study of patient perspectives of clinical trial participation during the COVID-19 pandemic.

Sagar Lonial, MD, FACP


Unmet Needs and Future Directions in Care in Multiple Myeloma

Closing out their discussion on the management of multiple myeloma, expert panelists highlight unmet needs and look toward future directions in care.

Catherine A. Shu, MD


Catherine A. Shu, MD, Reviews Findings of Cohort A of the Phase 1 CHRYSALIS-2 Trial in Pretreated EGFR+ NSCLC

Catherine A. Shu, MD, spoke about the most important findings from the phase 1 CHRYSALIS-2 trial for patients with previously treated EGFR-mutant non–small cell lung cancer who are administered amivantamab plus lazertinib.

Paul A. Moore, PhD


Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Oscar Escobar-Vidarte, MD


Signaling Pathways in the Relapse of Glioblastoma

Javier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Alexandra Garcilazo-Reyes, MD


Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma

This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.

Laurie H. Sehn, MD


Laurie H. Sehn, MD, on the Key Takeaways From the GO29365 Study in DLBCL

The preliminary findings of the extension arm of the phase 1b/2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma.

Surbhi Sidana, MD


Treatment with Teclistamab Following Progression on CAR-T in R/R MM

The panel shares their experiences with the sequencing of BCMA-targeting therapies in MM, with particular focus on treatment of patients who progress on CAR T-cell therapy with teclistamab.

Ricardo Ghelman, MD, PhD


Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations

This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.

Carlos Ortiz-Hidalgo, MD


Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor

In this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.

Artak Gevorgyan, MD


How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.